Recruiting

Testing shorter treatment schedules for drug-resistant tuberculosis

Plain-English translation of NCT06441006 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing whether people with fluoroquinolone-susceptible rifampicin-resistant tuberculosis (a type of drug-resistant TB) can be successfully treated with shorter medication schedules. Researchers are comparing three different treatment approaches using four TB medications: , , , and . The goal is to find out if the medication can work in 13 or 17 weeks instead of the standard 24 weeks.

Current TB treatment takes 24 weeks or longer, which is hard for patients to complete and strains healthcare resources. This trial exists to see if this medication can cure drug-resistant TB faster, which would help more patients finish treatment successfully and reduce the burden on health systems.

Do you qualify?

You likely qualify if…

you have been diagnosed with a specific type of drug-resistant tuberculosis confirmed by testing
you are at least 14 years old
you have a stable address and are willing to stay in contact with the study team during treatment
you are able to give written consent (or a parent/guardian can consent for you)
you are either HIV-negative or, if HIV-positive, willing to take specific HIV medications that work well with TB treatment

You likely don't qualify if…

you are allergic or sensitive to any of the TB medications being tested
you have severely low blood cell counts or liver or kidney problems
you are taking certain HIV or other medications that interact dangerously with the TB treatment
you are pregnant with a multiple pregnancy or less than 14 weeks pregnant

What participation looks like

If you join this study, you will take four TB medications by mouth once daily for either 13, 17, or 24 weeks, depending on which treatment group you are randomly assigned to. You will have regular clinic visits and may receive home visits or phone calls to check on your progress and monitor for side effects. The study lasts for several months and requires you to stay in contact with the research team and maintain a stable address where you can be reached.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Testing shorter treatment schedules for drug-resistant tuberculosis

What is this trial?

Do you qualify?

What participation looks like

Trial locations(6 sites)